Conversely, assessment of markers of BMD in humans in treatment for depression following 6 infusions of ketamine demonstrated a sustained decrease in OPN in both male and female patients lasting at least 26 days after the last infusion, with demonstration of sex differences in other bone markers assessed (165). Here, SPP1 is linked to depressive symptom measurement.